Marseille MET3 Conference presentation. 2nd April 2012.

1. www.bioindustrypark.eu - info@bioindustrypark.it
Fabrizio Conicella – conicella@bioindustrypark.it

2. Contents
1. Bioindustry Park Silvano Fumero and
bioPmed
2. Bioprotech: overview
3. Bioindustry Park and Bioprotech
4. Lesson learned

3. Bioindustry Park Silvano Fumero
 Science park
specialised in health
care
 22.000 sqm labs and
office spaces for
companies
 Conference center
 Consultancy in
biomanagement
 Incubator
 R&D service delivery
 R&D shared facility
 Cluster managing
www.bioindustrypark.eu company focused in
www.biopmed.eu health care: bioPmed

4. The bioPmed “smart”approach…
The “traditional approach”
(One problem, one technology, one solution)
The “NEW” approach”
(Converging technologies)
- Up to 250 companies working specifically in
health care
- Over xx.000 companies working in ICT,
Mechatronics, New Materials, textiles, etc
80 bioPmed cluster CORE MEMBERS
share the approach of an Healthcare cluster aiming at
“Overlapping different technological knowledge to reach innovative solutions to
unmet medical needs and ensure a better future
Impact on Industry-research collaborations

5. The bioPmed pillars of action
And its supporting intitutions
www.biopmed.eu

7. The bioPmed community
BioCulture
80 core
member

8. Why to internationalize???
• Problems are global, Markets are global, finance is more and
Companies& R&D
more global, science is global, , optimizing health care costs
is a global trend…......…..
• Big players are “global”: they are acting following a global
strategy
• Small/medium players are willing to be global but….
– Lack of culture and skills
– Too focused on scientific development more than to company
development
– Not enough resources
– Need for partnerships
• Critical mass in R&D and innovative companies become
critical factors for territorial development
Regions
• Financial resources are scarce: single actors and single
territories can’t afford the entire spectrum of investments of
R&D to be competitive in every sector
• Lower transfer of public resources to R&D facilities
• Need to maximise positive impact of investments realised
(job creation and sustainability)
• Local policies are interconnected (e.g. EU influence..)

9. Why to cooperate in the mediterranean
area?
• Advantages from the cooperative approach:
– Starting from local assets exploiting synergies between
territories
– Win-win activities: complementarity approach (value
effective)
– Exploiting in a cooperative way the best components of
a process also if they are located in a different territory
– Minimize “bad” competition
– Sustainability
– Minimize duplications of activities
It requires a cultural shift!!!!!

10. BioProtech Project Overview
Project full title: Improve research capacities of the Centre of Biotechnology
of Sfax (Tunisia) in Bio-Processes for biotech applications, tying up with the
European Research Area
keywords: Biotech, bioprocesses, joint research, technology
transfer, ERA, regional impact, research policies
Duration (month): 30, from 1st November 2010
Project coordinator: CBS Sfax
Call: FP7-INCO-2010-6: Integrating Europe's neighbours into the ERA -WIDE
activity
bioprotech.org
10

11. Project consortium partners
Participant No. Participant organisation name Short Name Country
1 (Coordinator) Centre of Biotechnology of Sfax CBS Tunisia
2 International Centre for Genetic ICGEB Italy
Engineering and Biotechnology
3 National Institute of Applied Sciences INSA France
of Toulouse
4 Steinbeis Research Center SFZ Germany
5 Bioindustry Park Silvano BiPCa Italy
Fumero/bioPMed
6 University of Claude Bernard Lyon UCBL France

12. Bioprotech project
WP3
WP 1
WP2
WP5
Dissemination WP4
Project management WP6

13. Bioprotech goals
The following objectives will be addressed by BioProtech:
 Improvement of the technological background and
research skills
 Build up the knowledge base for commercialisation of
research results
 Build up knowledge about European research funding
instruments
 Increase the visibility of CBS on a local and European
level
 Improvement of the future biotechnology development
at CBS, tying up with the European Research Area

14. TT support approach
Map existing technology transfer
activities
Task 2.1 Task 2.1
Global trends
analysis General
CBS situation Need analisys/matching
analysis with CBS analisys
Training, coaching
and awareness to
commercialisation of
research results
Local situation D2.1
Task 2.2
Report
D2.3 TT/networking Training D2.2
guidelines planning
Local situation
implementation Training D2.4
material
Local ecosystem Task 2.3 Build up local customer
action/clustering and
D2.5 supporter/collaborator
action network

15. Lesson learned..up to now
• Human resources are a key factor
• General training on TT is not perceived as useful:
specific/need focused training is well accepted/requested
• Avoid fire and forget activities: coaching and follow-up
caractherised by a specialistc/sectorial focus
• Community bulding approach as tool to growth, also
internationally
• Usually science is not a problem…exploitation at local
leve is a problem..
• Identify direct positive impact on the local system as a
driver
• It takes time…………

16. Example of support
• Start-up: Production of antigens, antibodies and
diagnosis kit developement (2008)
• Specific critical analisys of business idea (2010)
• Identification of scientifc assets/market assets/USP and
strategic advice (2010)
• Coaching in drafting business plan toghether with a
Tunisian consultants (2010)
• Support in developing a presentation for an elevator
pitch (US based investors) (2011). Identified as selected
project for a business trip in US for identification of
investors and analisys of market opportunities
BIOtechRDP

17. bioPmed @ Bioindustry Park Silvano Fumero S.p.A.
Via Ribes, 5
10010 Colleretto Giacosa (TO)
Italy
Tel. +39-0125-561311
Fax +39-0125-538350
info@biopmed.eu
www.biopmed.eu
Is the team that wins not www.bioindustrypark.eu
the single player…